Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Are The Forecasted Market Size Estimates For The Non-Insulin Therapies For Diabetes Market Between 2025 And 2029?
The non-insulin therapies for diabetes market has seen robust expansion in recent years. Its valuation is set to climb from $19.98 billion in 2024 to $21.21 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.1%. This historical growth can be linked to factors such as rising diabetes prevalence, heightened awareness of diabetes management, an increase in healthcare expenditure, lifestyle alterations leading to higher incidence rates, a surge in diagnoses, growing government initiatives for diabetes care, and increased investment in pharmaceutical R&D.
The non-insulin therapies for diabetes market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $26.98 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.2%. Factors contributing to this growth during the forecast period include the increasing incidence of diabetes, heightened awareness regarding diabetes management, the wider acceptance of combination therapies, a growing elderly demographic, increased spending on healthcare, the broadening scope of telemedicine, and an increasing preference for oral drug formulations. Key trends expected within the forecast timeframe encompass innovations in both oral and injectable medications, progress in drug delivery mechanisms, breakthroughs in oral peptide delivery, the integration of telemedicine and digital health technologies, and ongoing developments in combination treatment approaches.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16494&type=smp
What Are The Key Drivers Of Growth In The Non-Insulin Therapies For Diabetes Market?
The rising incidence of diabetes is anticipated to propel the expansion of the non-insulin therapies for the diabetes market moving forward. Diabetes is a chronic medical condition characterized by elevated blood glucose levels, occurring when the body fails to produce sufficient insulin or utilize it effectively. The increasing number of diabetes cases stems from factors such as sedentary lifestyles, unhealthy diets, genetic predisposition, aging populations, obesity, ethnicity, lack of awareness, limited access to healthcare, and environmental influences. Non-insulin therapies for diabetes aid in managing the condition by improving insulin sensitivity, reducing glucose production in the liver, enhancing glucose uptake in muscle cells, and improving overall glycemic control. For instance, in April 2023, The British Diabetic Association, a UK-based diabetes charity, published a report stating that 4.3 million individuals in the UK were diagnosed with diabetes. Registration data for 2021-22 revealed an increase of 148,951 cases compared to 2020-21. Moreover, over 2.4 million people in the UK are at high risk of developing type 2 diabetes. Thus, the escalating prevalence of diabetes is driving the growth of the non-insulin therapies for the diabetes market.
What Are The Key Segments In The Non-Insulin Therapies For Diabetes Market?
The non-insulin therapies for diabetesmarket covered in this report is segmented –
1) By Drug Class: Biguanides; Sulfonylureas; Thiazolidinedione’s; Alpha-Glucosidase Inhibitors; Dipeptidyl peptidase-4 (DPP-4) Inhibitors; Glucagon-like peptide-1 (GLP-1) Analogs; Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
2) By Route Of Administration: Oral; Intramuscular
3) By Distribution Channel: Retail Pharmacy; Hospital Pharmacy; Online Pharmacy
4) By Application: Monitoring; Diagnosis; Treatment; Other Applications
Subsegments:
1) By Biguanides: Metformin; Combination Of Metformin With Other Drugs
2) By Sulfonylureas: Glimepiride; Glipizide; Glyburide
3) By Thiazolidinediones: Pioglitazone; Rosiglitazone
4) By Alpha-Glucosidase Inhibitors: Acarbose; Miglitol
5) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin; Saxagliptin; Linagliptin; Alogliptin
6) By Glucagon-Like Peptide-1 (GLP-1) Analogs: Exenatide; Liraglutide; Dulaglutide; Semaglutide
7) By Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Canagliflozin; Dapagliflozin; Empagliflozin
What Trends Are Redefining The Non-Insulin Therapies For Diabetes Market Dynamics?
Major companies operating in the non-insulin therapies for diabetes market are developing personalized diabetes management systems to enhance patient outcomes through continuous monitoring, data analysis, and tailored treatment plans. A customized diabetes management system adapts care and supervision based on each patient’s unique needs, leveraging real-time data and analytics to improve care and results. For example, in November 2022, Eli Lilly and Company, a US-based pharmaceutical firm, launched the Tempo personalized diabetes management platform. The Tempo platform incorporates three key components: the Tempo Smart Button, the TempoSmart app, and the prefilled insulin pen, the Tempo Pen. These elements work in conjunction to offer individualized guidance for adults with diabetes. The technology is designed to assist adults with type 1 or type 2 diabetes and their healthcare providers in making informed, data-driven treatment decisions utilizing Lilly insulins.
Who Are The Core Companies Influencing The Non-Insulin Therapies For Diabetes Market Landscape?
Major companies operating in the non-insulin therapies for diabetes market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi, The Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Les Servier Laboratories, Sumitomo Dainippon Pharma Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Uni-Bio Science Group Ltd., Intarcia Therapeutics, Janssen Pharmaceuticals, Boan Biotech, SatRx LLC
Download The Full Report For Exclusive Market Findings:
What Regional Growth Trends Are Shaping The Non-Insulin Therapies For Diabetes Market Outlook?
North America was the largest region in the non-insulin therapies for diabetes market in 2024. The regions covered in the non-insulin therapies for diabetes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Non-Insulin Therapies For Diabetes Market Report:
https://www.thebusinessresearchcompany.com/customise?id=16494&type=smp
Browse Through More Reports Similar to the Global Non-Insulin Therapies For Diabetes Market 2025, By The Business Research Company
Insulin Patch Pumps Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/insulin-patch-pumps-global-market-report
Insulin Biosimilars Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/insulin-biosimilars-global-market-report
Non Injectable Insulin Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/non-injectable-insulin-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model